Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
Primary objective :
- To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of
SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent
major depressive episode.
Secondary objectives:
- To assess the safety profile of SR58611A 700 mg/d in comparison to placebo and to assess
plasma concentrations of the active metabolite.